Virtual drug design: Skp1-Skp2 inhibition targets cancer stem cells

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Cancer is characterized by dysregulated cellular pathways, making pathway inhibitors a key research focus.
• E3 ubiquitin ligases, like Skp2 (S-phase kinase-associated protein 2), are crucial for cellular function and implicated in various diseases when dysregulated.
• Overexpression of Skp2 is linked to poor cancer prognosis and metastasis, establishing it as a validated drug target.

Purpose of the Study:

• To identify and validate a novel small molecule inhibitor targeting Skp2 E3 ligase activity.
• To evaluate the efficacy of the Skp2 inhibitor in preclinical cancer models.

Main Methods:

• Integrated virtual high-throughput drug screening.
• Experimental validation of identified Skp2 inhibitor.
• Assessment of inhibitor effects on cancer stemness, chemotherapy sensitivity, aerobic glycolysis, and cellular senescence in animal tumor models.

Main Results:

• Identification of a novel small molecule that selectively inhibits Skp2 E3 ligase activity.
• The Skp2 inhibitor demonstrated efficacy in restricting cancer stemness across multiple tumor models.
• Inhibition of Skp2 potentiated sensitivity to chemotherapeutic agents and reduced tumor growth by attenuating aerobic glycolysis and inducing cellular senescence.

Conclusions:

• A novel Skp2 inhibitor has been identified with potential therapeutic applications in cancer treatment.
• Targeting Skp2 offers a promising strategy to overcome cancer stemness and enhance chemotherapy efficacy.
• The findings highlight the role of Skp2 in regulating aerobic glycolysis and cellular senescence, providing new avenues for cancer therapy.